<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 11pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WASHINGTON, DC 20549&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER">&nbsp;<DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><B>FORM 8-K</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><B>CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(d) OF<BR>
THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">&nbsp;Date Of Report
(Date Of Earliest Event Reported): February 6, 2012</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1.5pt solid; font-size: 18pt; font-weight: bold; text-align: center">NORTHWEST BIOTHERAPEUTICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; font-weight: bold; text-align: center">Delaware</TD>
    <TD STYLE="width: 2%; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">0-33393</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">94-3306718</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">(State Or Other Jurisdiction Of Incorporation)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">(Commission File Number)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>4800 Montgomery Lane, Suite 800, Bethesda,
MD 20814 </U><BR>
(Address Of Principal Executive Offices) (Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&rsquo;s Telephone Number, Including
Area Code (240) 497-9024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-left: -2.25pt">
<TR>
    <TD STYLE="width: 3%; text-align: center"><FONT STYLE="font: 10pt Wingdings">o</FONT></TD>
    <TD STYLE="width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 96%; vertical-align: top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings">o</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings">o</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
<TR>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings">o</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 1.01 Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On January 31, 2012, the
Registrant completed  financings involving several parties and a series of tranches.&nbsp; The Registrant entered into
two convertible notes totaling $605,000 with Toucan Partners (the &ldquo;Toucan Notes&rdquo;).&nbsp; These Toucan Notes
provided for OID of ten percent and an annual interest rate of six percent.&nbsp; The Toucan Notes are convertible at any
time after closing. The conversion price is equal to a five percent discount from the market price at the time of conversion.
The Toucan Notes are payable on demand, with one week prior notice.&nbsp; The Toucan Notes include one warrant for each share
of the Company&rsquo;s common stock into which the Toucan Notes are convertible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Registrant entered into a $200,000
convertible note with an affiliate of the Company (the &ldquo;Affiliate Note&rdquo;). The Affiliate Note provided for OID of
ten percent and an annual interest rate of six percent.&nbsp; The Affiliate Notes are convertible at any time after
closing.&nbsp; The conversion price is equal to a five percent discount from the market price at the time of
conversion.&nbsp;&nbsp; The Affiliate Note is payable on demand, with one week prior notice. The Affiliate Note includes one
warrant for each share into which the  Affiliate Note is  convertible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">The Registrant
entered into an $802,000 convertible note with a non-affiliated investor (the &ldquo;Note&rdquo;), completing a series of transactions
initially entered into on January 19,&nbsp;2011, with the investor. The Note provided for original issue discount (OID) of ten
percent and an annual interest rate of nine percent.&nbsp; The Note attributed $220,000 of the proceeds as a payment in lieu of
the Company drawing upon an earlier convertible borrowing obligation of $666,666 which would have carried a 40% discount to the
market price upon conversion. &nbsp;The Note also provided for an additional $500,000 advance to the Company and is convertible
at any time after closing.&nbsp; The conversion price for the $500,000 tranche is equal to a twenty percent discount from the market
price at the time of conversion. The conversion price for the $220,000 tranche is equal to a fifteen percent discount from the
market&nbsp;price at the time of conversion</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 3.02 Unregistered Sales of Equity Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The securities described in Item 1.01 above
were offered and sold in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act of 1933,
as amended (&ldquo;Securities Act&rdquo;), and Rule 506 of Regulation D promulgated thereunder. The agreements executed in connection
with this sale contain representations to support the Registrant&rsquo;s reasonable belief that the investor had access to information
concerning the Registrant&rsquo;s operations and financial condition, the investor acquired the securities for their own account
and not with a view to the distribution thereof in the absence of an effective registration statement or an applicable exemption
from registration, and that the investor was sophisticated within the meaning of Section 4(2) of the Securities Act and was an
&ldquo;accredited investor&rdquo; (as defined by Rule 501 under the Securities Act). In addition, the issuances did not involve
any public offering; the Registrant made no solicitation in connection with the sale other than communications with the investor;
the Registrant obtained representations from the investor regarding its investment intent, experience and sophistication; and the
investor either received or had access to adequate information about the Registrant in order to make an informed investment decision.
At the time of their issuance, the securities will be deemed to be restricted securities for purposes of the Securities Act, and
the certificates representing the securities shall bear legends to that effect. The securities may not be resold or offered in
the United States without registration or an exemption from registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt">NORTHWEST BIOTHERAPEUTICS, INC</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 44%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Dated: February 6, 2012</TD>
    <TD STYLE="padding-right: 0.8pt">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding-right: 0.8pt; font-style: italic">/s/ Linda Powers</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Name:&nbsp; Linda Powers</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Title: Chief Executive Officer and Chairman</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v301455_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 15759}]
{"company-data": {"conformed-name": "NORTHWEST BIOTHERAPEUTICS INC", "cik": "0001072379", "assigned-sic": "2834", "irs-number": "943306718", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-33393", "film-number": "12574438"}, "business-address": {"street1": "7600 WISCONSIN AVE.", "street2": "SUITE 750", "city": "BETHESDA", "state": "MD", "zip": "20814", "phone": "4256083008"}, "mail-address": {"street1": "7600 WISCONSIN AVE.", "street2": "SUITE 750", "city": "BETHESDA", "state": "MD", "zip": "20814"}}
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date Of Report
(Date Of Earliest Event Reported): February 6, 2012
NORTHWEST BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
0-33393
94-3306718
(State Or Other Jurisdiction Of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
4800 Montgomery Lane, Suite 800, Bethesda,
MD 20814
(Address Of Principal Executive Offices) (Zip Code)
Registrant's Telephone Number, Including
Area Code (240) 497-9024
Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
On January 31, 2012, the
Registrant completed  financings involving several parties and a series of tranches.  The Registrant entered into
two convertible notes totaling $605,000 with Toucan Partners (the "Toucan Notes").  These Toucan Notes
provided for OID of ten percent and an annual interest rate of six percent.  The Toucan Notes are convertible at any
time after closing. The conversion price is equal to a five percent discount from the market price at the time of conversion.
The Toucan Notes are payable on demand, with one week prior notice.  The Toucan Notes include one warrant for each share
of the Company's common stock into which the Toucan Notes are convertible.
The Registrant entered into a $200,000
convertible note with an affiliate of the Company (the "Affiliate Note"). The Affiliate Note provided for OID of
ten percent and an annual interest rate of six percent.  The Affiliate Notes are convertible at any time after
closing.  The conversion price is equal to a five percent discount from the market price at the time of
conversion.   The Affiliate Note is payable on demand, with one week prior notice. The Affiliate Note includes one
warrant for each share into which the  Affiliate Note is  convertible.
The Registrant
entered into an $802,000 convertible note with a non-affiliated investor (the "Note"), completing a series of transactions
initially entered into on January 19, 2011, with the investor. The Note provided for original issue discount (OID) of ten
percent and an annual interest rate of nine percent.  The Note attributed $220,000 of the proceeds as a payment in lieu of
the Company drawing upon an earlier convertible borrowing obligation of $666,666 which would have carried a 40% discount to the
market price upon conversion.  The Note also provided for an additional $500,000 advance to the Company and is convertible
at any time after closing.  The conversion price for the $500,000 tranche is equal to a twenty percent discount from the market
price at the time of conversion. The conversion price for the $220,000 tranche is equal to a fifteen percent discount from the
market price at the time of conversion
.
Item 3.02 Unregistered Sales of Equity Securities.
The securities described in Item 1.01 above
were offered and sold in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act of 1933,
as amended ("Securities Act"), and Rule 506 of Regulation D promulgated thereunder. The agreements executed in connection
with this sale contain representations to support the Registrant's reasonable belief that the investor had access to information
concerning the Registrant's operations and financial condition, the investor acquired the securities for their own account
and not with a view to the distribution thereof in the absence of an effective registration statement or an applicable exemption
from registration, and that the investor was sophisticated within the meaning of Section 4(2) of the Securities Act and was an
"accredited investor" (as defined by Rule 501 under the Securities Act). In addition, the issuances did not involve
any public offering; the Registrant made no solicitation in connection with the sale other than communications with the investor;
the Registrant obtained representations from the investor regarding its investment intent, experience and sophistication; and the
investor either received or had access to adequate information about the Registrant in order to make an informed investment decision.
At the time of their issuance, the securities will be deemed to be restricted securities for purposes of the Securities Act, and
the certificates representing the securities shall bear legends to that effect. The securities may not be resold or offered in
the United States without registration or an exemption from registration.
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NORTHWEST BIOTHERAPEUTICS, INC
Dated: February 6, 2012
By:
/s/ Linda Powers
Name:  Linda Powers
Title: Chief Executive Officer and Chairman
3